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Giardia lamblia is the etiologic agent of giardiasis, a water-borne infection that
is prevalent throughout the world. The need for new therapeutics for the
treatment of giardiasis is of paramount importance. Owing to the ubiquitous
nature of kinases and their vital importance in organisms, they are potential
drug targets. In this paper, the ﬁrst structure of a cyclin-dependent kinase
(CDK) from G. lamblia (GlCDK; UniProt A8BZ95) is presented. CDKs are
cell-cycle-associated kinases that are actively being pursued as targets for
anticancer drugs as well as for antiparasitic chemotherapy. Generally, a CDK
forms a complex with its associated cyclin. This CDK–cyclin complex is active
and acts as a serine/threonine protein kinase. Typically, CDKs are responsible
for the transition to the next phase of the cell cycle. Although the structure of
GlCDK with its associated cyclin was not solved, the 1.85 A ˚ resolution structure
of apo GlCDK and a 2.0 A ˚ resolution structure of GlCDK in complex with
adenosine monophosphate are presented and the structural differences from the
orthologous human CDK2 and CDK3 are discussed.
1. Introduction
1.1. Giardia lamblia
G. lamblia (also referred to as G. duodenalis or G. intestinalis)i sa
water-borne ﬂagellated parasite that causes giardiasis in humans.
Host-to-host transference of Giardia cysts takes place via the fecal–
oral route (Dawson & House, 2010). This allows the protozoan to
infect the next generation of hosts through a diverse range of
mechanisms: person to person, animal to human or by contact with
contaminated water and food (Plutzer et al., 2010). Outbreaks
commonly occur in areas with inadequate water treatment, especially
developing countries, where infection rates can be higher than 50%
of the total population (World Health Organization, 1992). Giardia
is one of the leading protozoan causes of gastrointestinal illness
worldwide and has joined the ranks of the WHO Neglected Diseases
Initiative (Flanagan, 1992; Savioli et al., 2006).
G. lamblia has a two-stage lifecycle: the cyst and the trophozoite.
The cyst is able to pass intact through the stomach and excysts in the
small intestine. The trophozite binds to the upper intestine, causing
malabsorption and the symptoms of giardiasis (Birkeland et al., 2010).
Giardiasis in children, who are at a higher risk of infection, is asso-
ciated with a failure to thrive and impaired cognitive function and can
lead to death (Savioli et al., 2006; Centers for Disease Control and
Prevention, 2010).
The current treatment options for Giardia are limited. Furazoli-
done and quinacrine have availability problems and metronidazole
and paromomycin are not FDA-approved for the treatment of giar-
diasis in the US (The Medical Letter,2010). There is also concern that
resistance is emerging to the most commonly used therapeutic,
metronidazole (Upcroft et al., 2009). It is clear with G. lamblia being
such a ubiquitous pathogen that new drug therapies are of the utmost
importance to the global community.1.2. Cyclin-dependent kinases
Cyclin-dependent kinases (CDKs) are typically described as
regulators of the cell cycle. Different CDKs become activated via
their cyclin partners at different times during cell-cycle progression
(Vermeulen et al., 2003). A CDK inhibitor would lock the cell cycle
in place and prevent growth, which is the precise reason why CDK
inhibitors are under clinical trial for various types of cancer (Rossi et
al., 2006).
CDKs have not only been found in humans and higher-level
organisms but also in lower-level organisms such as protozoa (Naula
et al., 2005). Thus, the use of CDK inhibitors could have far-reaching
implications. CDK inhibitors have previously been shown to accel-
erate apoptosis in mammalian cells (Rossi et al., 2006). As mentioned
above, human CDK inhibitors are currently receiving an inﬂux of
pharmaceutical investment for oncological indications. The CDK
from G. lamblia (GlCDK) has two human homologues with similar
overall amino-acid identities of over 50%, with the other human
homologues all having above 33% similarity (Table 1). All of the
human CDKs presented in Table 1 have been structurally elucidated,
with the exception of human CDK3. Given that human CDKs can be
inhibited, leading to apoptosis, GlCDK may also be a potential drug
target for the treatment of giardiasis. The lack of signiﬁcant overall
amino-acid sequence identity to human CDKs indicates that it may
be possible to selectively inhibit the Giardia protein. The structural
investigations reported here were performed in order to further
investigate GlCDK as a drug target.
2. Methods
2.1. Protein expression and purification
The gene encoding the CDK from G. lamblia (GlCDK; UniProt
A8BZ95) was PCR-ampliﬁed in a 96-well format using genomic DNA
as a template. The primers were designed with an additional ligation-
independent cloning (LIC; Aslanidis & de Jong, 1990) sequence at
their 50 ends that was complementary to the LIC sequence in the
plasmid vector. The puriﬁed PCR products were then cloned via LIC
into the AVA0421 expression vector (Quartley et al., 2009), which
provided a C3-cleavable six-histidine (His6) tag at the N-terminus of
the expressed protein with sequence MAHHHHHHMGTLEAQTQ/
GPGS (the protease cleavage site is indicated by a slash). The
recombinant plasmid was then transformed into Escherichia coli
Rosetta Oxford strain [BL21*(DE3)-R3-pRARE2] cells for expres-
sion testing (Mehlin et al., 2006; Choi et al., 2011).
A starter culture of LB broth with appropriate antibiotics was
grown for  18 h at 310 K. ZYP-5052 auto-induction medium was
freshly prepared as per UW-PPG protocols (Studier, 2005; Choi et al.,
2011). Antibiotics were added to 2 l bottles of sterile auto-induction
medium. The bottles were inoculated with all of the overnight culture.
The inoculated bottles were then placed into a LEX Bioreactor
(Harbinger Biotechnology, Toronto, Ontario). Cultures were grown
for  24 h at 298 K; the temperature was then reduced to 288 K and
the cultures were grown for a further  60 h. To harvest, the medium
was centrifuged at 4000g for 20 min at 277 K. The cell paste was then
ﬂash-frozen in liquid nitrogen and stored at 193 K.
The frozen pellet was thawed and puriﬁed as per the SSGCID
protocol (Bryan et al., 2011). Brieﬂy, the pellet was completely
resuspended in lysis buffer (20 mM HEPES pH 7.2–7.4, 300 mM
NaCl, 5% glycerol, 30 mM imidazole, 0.5% CHAPS, 10 mM MgCl2,
3m M  -mercaptoethanol, 1.3 mg ml
 1 protease-inhibitor cocktail
and 0.05 mg ml
 1 lysozyme). The resuspended cell pellet was then
disrupted on ice for 15 min using a Branson Digital Soniﬁer 450D (set
to 70% amplitude, with alternating cycles of 5 s pulse-on and 10 s
pulse-off). The cell debris was incubated with 20 units ml
 1
Benzonase nuclease (EMD Chemicals,Gibbstown, New Jersey,USA)
at room temperature for at least 40 min and was then clariﬁed by
centrifugation with a Sorvall RC5 at 10 000 rev min
 1 for 60 min at
277 K in a F14S Rotor (Thermo Fisher). The His6-tagged GlCDK was
separated from the clariﬁed cell lysate by IMAC on a HisTrap FF 5 ml
column (GE Biosciences, Piscataway, New Jersey, USA) equilibrated
with binding buffer (20 mM HEPES pH 7.0, 300 mM NaCl, 5%
glycerol, 30 mM imidazole, 1 mM TCEP). The recombinant GlCDK
was eluted in wash buffer by the addition of 500 mM imidazole with a
step elution and was further resolved by size-exclusion gel chroma-
tography (SEC; Superdex 75 26/60, GE Biosciences). The His6 afﬁnity
tag was not removed from the protein. Pure fractions collected in
SEC buffer (20 mM HEPES pH 7.0, 300 mM NaCl, 2 mM DTT and
5% glycerol) as a single peak were analyzed using SDS–PAGE and
Simply Blue Safestain (Invitrogen Corp, Carlsbad, California, USA).
The protein was then pooled, concentrated to 27.3 mg ml
 1, ﬂash-
frozen and stored at 193 K in SEC buffer. The puriﬁed protein in this
ﬁnal buffer was used in the crystallization trials.
2.2. Crystallization
Two sparse-matrix screens were set up with puriﬁed GlCDK at a
ﬁnal concentration of 25.2 mg ml
 1 using the JCSG+, Cryo (Emerald
BioStructures, Bainbridge Island, Washington, USA), PACT and
ProPlex (Molecular Dimensions, Apopka, Florida, USA) screens
following an extended Newman’s strategy (Newman et al., 2005).
0.4 ml protein solution was mixed with 0.4 ml reservoir solution and
equilibrated against 100 ml reservoir solution using 96-well Compact
Jr Crystallization plates (Emerald BioStructures). Crystals were
obtained in several PEG-containing conditions. Crystals that were
suitable for diffraction studies were found in PACT screen condition
F9: 200 mM sodium/potassium tartrate, 100 mM Bis-Tris propane pH
6.5, 20% PEG 3350. Native GlCDK crystals were cryoprotected by
short soaks in buffers consisting of reservoir solution with an
additional 10 and 20% glycerol and were then vitriﬁed by plunging
them into liquid nitrogen. For the ligand-bound structure, a crystal
from the same drop was harvested in a soaking buffer consisting of
structural communications
Acta Cryst. (2011). F67, 1084–1089 Leibly et al.   Cyclin-dependent kinase 1085
Table 1
Amino-acid homology between human CDKs and G. lamblia CDK.
Human CDK CDK3† CDK2 CDK7 CDK6 CDK4 CDK9
Amino-acid sequence identity (%) 57.3 55.4 41.7 38.7 36.0 34.3
† The structure of CDK3 has not been elucidated.
Table 2
Data-collection statistics.
Values in parentheses are for the highest of 20 resolution shells.
Apo AMP-bound
Wavelength (A ˚ ) 1.5418 1.5418
Space group P212121 P212121
Unit-cell parameters (A ˚ ) a = 52.72, b = 73.05, c = 75.01 a = 53.24, b = 73.18, c = 75.38
Resolution range (A ˚ ) 20–1.85 (1.90–1.85) 20–2.00 (2.05–2.00)
Mean I/ (I) 19.6 (2.1) 16.4 (2.3)
Rmerge† 0.045 (0.498) 0.079 (0.650)
Completeness (%) 99.7 (99.6) 99.1 (92.9)
Multiplicity 5.0 (3.0) 6.6 (3.9)









i IiðhÞ.200 mM sodium/potassium tartrate, 100 mM Bis-Tris propane, 25%
PEG 3350, 1 mM adenosine monophosphate (AMP) and 1 mM
MgCl2. After an overnight soak, the crystal was vitriﬁed as before by
plunging it directly into liquid nitrogen.
2.3. Data collection and structure determination
Data sets were collected in-house from native and AMP-bound
crystals at the Cu K  wavelength using a Rigaku SuperBright FR-E
+
rotating-anode X-ray generator equipped with Osmic VariMax HF
optics and a Saturn 944+ CCD detector (Table 2). For each data set,
720 images were collected with a ﬁne ’-slicing of 0.25  per image. The
diffraction data were reduced in space group P212121 using XDS/
XSCALE (Kabsch, 2010) to 1.85 A ˚ resolution.
The packing density (Matthews, 1968) suggested the presence of
oneGlCDK molecule per asymmetric unit, with aVMof 1.93 A ˚ 3 Da
 1
and 36% solvent content. A search of the PDB for sequence
homology yielded human cyclin-dependent kinase CDK2 (PDB
entry 1oit; Anderson et al., 2003) as the closest homolog, with 56%
sequence identity. The search model was derived from monomer A
of PDB entry 1oit using the CCP4( W i n net al., 2011) program
CHAINSAW (Stein, 2008). Molecular replacement was performed
with the CCP4 program Phaser (McCoy et al., 2007) using data
between 20 and 3.0 A ˚ resolution; one molecule could be placed with
high scores (RFZ = 12.5, TFZ = 17.7, LLG = 379, LLGref = 502). The
model was then iteratively extended manually using Coot (Emsley et
al., 2010) followed by cycles of reciprocal-space reﬁnement with the
CCP4 program REFMAC5; H atoms were added in riding positions
(Murshudov et al., 2011).
The native structure could be reﬁned at 1.85 A ˚ resolution to an
Rwork of 0.184 and an Rfree of 0.236 with good stereochemistry
(Table 3). The observed structure extended from residues Ser11 to
Pro308 with three exceptions (Fig. 1a). Three loops could not be
modelled owing to weak electron density: Glu51–Thr58, Ser147–
Glu151 and Ile168–Ile178. 209 water molecules were located. Four
Ramachandran plot outliers were observed in Coot: Ile12 and Glu49,
structural communications
1086 Leibly et al.   Cyclin-dependent kinase Acta Cryst. (2011). F67, 1084–1089
Figure 1
Structures of CDK kinase from G. lamblia. The apo structure (a) and the AMP-bound structure (b) are very similar. In (b) the OMIT Fo   Fc electron density for AMP is
shown in green, contoured at 3.0 . A close up of the OMIT density for AMP is shown in stereo representation in (c). The  A-weighted electron-density maps are contoured
at 1  for the 2Fo   Fc map (blue, carved with a 2 A ˚ radius around the AMP molecule) and at  3  for the Fo   Fc maps (green/red, carved with a 4 A ˚ radius around the AMP
molecule).which are both adjacent to disordered regions, and Arg135 and
Thr261, which both have well deﬁned electron density.
The AMP-bound structure was solved by direct reﬁnement of the
apo structure after stripping off all solvent molecules. The structure
was reﬁned at 2.0 A ˚ resolution to an Rwork of 0.196 and an Rfree of
0.265 with good stereochemistry (Table 3 and Fig. 1b). The observed
structure extended from residues Ser11 to Pro308, but again three
loops could not be located owing to weak electron density: Glu51–
Gly57, Ser147–Ser150 and Gly167–His175. 144 water molecules were
modelled. Good OMIT density was observed for one AMP molecule
(Fig. 1c). The same Ramachandran plot outliers were observed as for
the native protein, with the exception of Ile12.
The difference between Rcryst and Rfree for the AMP-bound data
set is 6.9%. This is higher than our usual goal in SSGCID for
reﬁnement (<5%). However, we do not see signiﬁcant hints of over-
reﬁnement. The AMP-bound structure was re-reﬁned with various
numbers of TLS groups, which did not result in signiﬁcant improve-
ments in the R factors: Rcryst/Rfree were 0.196/0.265 for no TLS, 0.192/
0.260 for one TLS group and 0.191/0.257 for ﬁve TLS groups (as
suggested by TLSMD; Painter & Merritt, 2006). Most importantly,
the maps of the three reﬁnements were virtually identical. Owing to
this, the deposited structures were not reﬁned with TLS parameters.
Additionally, we have observed hundreds of kinase structures
through efforts by SSGCID and Emerald BioStructures and have
found that the functional ﬂexibility of the molecule is not properly
described by the common reﬁnement parameterization. This
frequently renders high reﬁnement R factors; nevertheless, the
electron-density maps are of good quality.
3. Results and discussion
Full-length GlCDK was puriﬁed with crystallizable quality under
standard puriﬁcation conditions. Diffraction-quality crystals were
obtained without the need for optimization. Additionally, AMP was
able to bind to the apo protein during an overnight soak.
A1 . 8 5A ˚ resolution apo data set was collected together with a
2.0 A ˚ resolution data set for the AMP-bound protein using an in-
house X-ray beam. The relatively high sequence identity to several
human CDKs (Fig. 2) allowed determination of the GlCDK structure
by molecular replacement. The protein exhibited the expected fold
for a CDK and existed as a monomer in the asymmetric unit (Fig. 3a).
There is little structural variation between the apo and ligand-
bound forms: 273 C
  atoms superimposed with an r.m.s.d. of 0.27 A ˚ .
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Figure 2
Amino-acid sequence alignment between GlCDK, human CDK3 and human CDK2.
Table 3
Reﬁnement and model statistics.
Values in parentheses are for the highest of 20 resolution shells.
Apo AMP-bound
Resolution range (A ˚ ) 20–1.85 (1.90–1.85) 20–2.00 (2.05–2.00)
Rcryst† 0.184 0.196
Rfree† 0.236 0.265
R.m.s.d. bonds (A ˚ ) 0.018 0.018
R.m.s.d. angles ( ) 1.59 1.61
Protein atoms 2188 2212
Nonprotein atoms 209 167
Mean B factor (A ˚ 2) 31.7 23.7
Residues in favored region 250 [95%] 253 [95%]
Residues in allowed region 8 [3.1%] 9 [3.4%]
Residues in disallowed region 4 [1.5%] 3 [1.1%]
MolProbity‡ score [percentile] 1.62 [90th] 1.97 [76th]









i IiðhklÞ. The free R factor was calculated
using an equivalent equation as for Rcryst with 5% of the reﬂections that were omitted
from the reﬁnement. ‡ Chen et al. (2010)Both structures contained three loops that could not be fully
modelled owing to weak electron density. Residues Glu51–Thr58,
Ser147–Glu151 and Ile168–Ile178 of the apo structure and residues
Glu51–Gly57, Ser147–Ser150 and Gly167–His175 of the AMP-bound
protein were not observed in our structures. However, the corre-
sponding residues have been observed in several of the human CDK
structures deposited in the PDB (see Fig. 3b). NCBI annotation
indicates that residues Gly158–Pro169 and Phe173–Trp181 are part
of the kinase-activation loop. The weak electron density for residues
Ile168–Ile178 of the apo structure and residues Gly167–His175 of
the AMP-bound structure is consistent with ﬂexibility of the kinase-
activation loop. Fig. 3(b) depicts a superposition of GlCDK and
human CDK2. Although the activation loop is not fully observed in
the GlCDK structure, structural differences are apparent.
The unobserved activation loop contains the Thr174 residue that
is phosphorylated in CDKs for full kinase activity (DeBondt et al.,
1993); human CDK1, CDK2 and CDK3 have the conserved sequence
TFHEIVTwhich corresponds to Thr160–Thr167 of CDK2. Thr160 is
theresidue that isphosphorylated for full activity ofCDK2 (DeBondt
et al., 1993). The homologous sequence of GlCDK consists of TFH-
EIIT (Thr174–Thr180). The inhibitory phosphorylation sites Thr25
and Tyr26, which correspond to residues Thr14 and Tyr15 of CDK2,
are observed and are unphosphorylated in GlCDK.
Furthermore, the unobserved loops Glu51–Thr58 (apo) and
Glu51–Gly57 (AMP-bound) are predicted to be part of the CDK–
cyclin interface that contains the residues Glu53–Val55 and Gly57
(NCBI annotation). This region corresponds to the PSTAIRE
domain in human CDK (DeBondt et al., 1993). The equivalent
domain in GlCDK consists of PGTAIRE (Pro56–Glu62). Pro56–
Gly57 remain unobserved in the AMP-bound structure and in the
apo structure. This sequence is conserved between the GlCDK and
human CDK structures, with differences in the structures of the
preceding loops between the GlCDK structure and the human CDK2
structure (PDB entry 1hcl; Schulze-Gahmen et al., 1996).
The ﬁnal conserved CDK regulatory GDSEID motif consists of
Gly219–Asp224 of the Giardia protein. The amino-acid sequence is
fully conserved between the Giardia and human proteins and there
are no structural variations. Superposition of the ATP-binding site
between GlCDK and human CDK2 shows slight variations in the
pocket but no signiﬁcant structural variations (Schulze-Gahmen et al.,
1996).
A superposition of full-length GlCDK and human CDK2 (Fig. 3)
shows the expected structural homology of the proteins, with an
r.m.s.d. of around 1.26 A ˚ over 266 C
  atoms. Although the overall
structure is very similar to those of the human CDKs, the sequence
deviations in key regions observed in this study indicates that it may
be possible to selectively inhibit GlCDK. Given the large number of
inhibitor-bound structures of human CDKs available in the PDB, it
may be possible to model inhibitors in the GlCDK active site. This
can serve as a starting point for GlCDK inhibitor development. The
accessibility of the ATP-binding site to soaking suggests that similar
soaks with ATP-competitive kinase inhibitors would be successful
and could aid a structure-based drug-development approach. Given
that human CDKs can be inhibited, leading to apoptosis, GlCDK may
also be a potential drug target for the therapy of giardiasis. Indeed,
apoptotic cell death has been observed in a variety of protozoan
pathogens, including Giardia (Chose et al., 2003), and it seems likely
that CDK inhibition would lead to apoptotic cell death in Giardia.
Further efforts need to be made to determine the native cyclin
partner for the Giardia protein. To date, no kinase assays on this
protein have been performed in our laboratory. It is unknown
whether the cyclin is necessary for full activity in this case, although
cyclins are generally required for full activity of CDKs. It is
conceivable that cyclins from another species may be able to serve as
a partner for activity assays or structure determination and this would
enable the further development of inhibitors for GlCDK without
de novo protein production. The Giardia genome reveals at least six
cyclins that have been annotated, including cyclin A and cyclin B
homologs (http://giardiadb.org), and co-expression and testing with
the CDK described here is feasible.
4. Conclusion
This paper describes the puriﬁcation and structure determination
of the ﬁrst CDK from the pathogenic protozoon G. lamblia.T h e
presented 1.85 A ˚ resolution structure has structural homology to
human CDK2 (PDB entry 1hcl) and a slightly higher sequence
structural communications
1088 Leibly et al.   Cyclin-dependent kinase Acta Cryst. (2011). F67, 1084–1089
Figure 3
GlCDK (PBD entry 3gc0) superposed with human CDK2 (PDB entry 1hcl; Schulze-Gahmen et al., 1996). The Giardia protein is depicted in the same colours as in Fig. 1.
CDK2 is depicted with cyan  -strands, red  -helices and blue loops. The insert depicts the different conformations of the activation loop in the two structures. Most of the
activation loop is disordered in GlCDK.homology to human CDK3, which to date has no solved structure.
This protein is from a class of validated drug targets; however, further
work needs to be performed to determine whether the Giardia
protein can be selectively inhibited over the human CDKs. To date,
25 G. lamblia protein structures have been deposited in the PDB.
However, this is the ﬁrst Giardia CDK structure to be determined.
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